Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17505042 | 0.92 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2CTSBPOLB | |
| SCHEMBL20175319 | 0.88 | GAA (0.43) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL17505036 | 0.86 | ALDH1A1 (0.39) | ALDH1A1KDM4ESMN1; SMN2CTSBPOLB | |
| SCHEMBL5519155 | 0.85 | GAA (0.47) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL499372 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4ECTSBPOLBLMNA | |
| SCHEMBL5518656 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL20175322 | 0.81 | CHRNB4 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTCHRNB4 | |
| SCHEMBL499016 | 0.81 | NOS3 (0.48) | ALDH1A1KDM4EMAPTCHRNB4CHRNA3 | |
| SCHEMBL17505044 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAGAAMAPT | |
| SCHEMBL17505037 | 0.80 | MAPT (0.40) | ALDH1A1LMNAGAAMAPTCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141922-A1 | BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | L'OREAL (FR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141922-A1 | BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | XDH, KRT18, CYC1 | ALDH1A1 1230/4885KDM4E 2585/4885SMN1; SMN2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.